Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GH Research ( (GHRS) ) has issued an update.
GH Research PLC announced its participation in a fireside chat at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry and Epilepsy Summit, held virtually on September 17-18, 2025. This participation underscores the company’s engagement in industry discussions and its commitment to advancing neuropsychiatric and epilepsy treatments.
The most recent analyst rating on (GHRS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC operates in the neuropsychiatry and epilepsy industry, focusing on novel mechanisms to address these conditions.
Average Trading Volume: 265,079
Technical Sentiment Signal: Buy
Current Market Cap: $774.1M
For detailed information about GHRS stock, go to TipRanks’ Stock Analysis page.